S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:RMTI

Rockwell Medical - RMTI Stock Forecast, Price & News

$1.05
-0.04 (-3.67%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.01
$1.09
50-Day Range
$0.84
$1.39
52-Week Range
$0.84
$7.15
Volume
72,280 shs
Average Volume
95,000 shs
Market Capitalization
$9.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Rockwell Medical MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
661.9% Upside
$8.00 Price Target
Short Interest
Healthy
1.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
0.29mentions of Rockwell Medical in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.96) to ($0.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

RMTI stock logo

About Rockwell Medical (NASDAQ:RMTI) Stock

Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

Receive RMTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rockwell Medical and its competitors with MarketBeat's FREE daily newsletter.

RMTI Stock News Headlines

Rockwell Medical (NASDAQ: RMTI)
Rockwell Medical Announces Second Quarter 2022 Results
Rockwell Medical drops 14% as CEO departs
See More Headlines
Receive RMTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rockwell Medical and its competitors with MarketBeat's FREE daily newsletter.

RMTI Company Calendar

Last Earnings
11/15/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/13/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:RMTI
CUSIP
77437410
Employees
300
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+661.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-32,670,000.00
Pretax Margin
-36.70%

Debt

Sales & Book Value

Annual Sales
$61.93 million
Book Value
$1.72 per share

Miscellaneous

Free Float
9,134,000
Market Cap
$9.88 million
Optionable
Optionable
Beta
1.05

Social Links


Key Executives

  • Mr. Russell L. Skibsted M.B.A. (Age 63)
    Exec. VP, CFO & Chief Bus. Officer
    Comp: $598.92k
  • Dr. Mark Strobeck Ph.D. (Age 51)
    Pres, CEO & Director
  • Mr. Paul E. McGarry (Age 54)
    SVP of Fin. & Chief Accounting Officer
  • Ms. Megan C. Timmins (Age 49)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Mr. James A. McCarthy
    Sr. VP of Bus. & Corp. Devel.
  • Mr. Timothy T. Chole
    Sr. VP of Sales & Marketing
  • Dr. Marc L. Hoffman M.D. (Age 61)
    Chief Medical Officer
  • Ms. Heather R. Hunter
    Sr. VP & Chief Corp. Affairs Officer
  • Mr. David J. Kull (Age 54)
    Sec.
  • Mr. Jason Finkelstein
    Investor Relations Representative













RMTI Stock - Frequently Asked Questions

Should I buy or sell Rockwell Medical stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rockwell Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RMTI shares.
View RMTI analyst ratings
or view top-rated stocks.

What is Rockwell Medical's stock price forecast for 2023?

1 Wall Street research analysts have issued 12-month price objectives for Rockwell Medical's shares. Their RMTI share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 661.9% from the stock's current price.
View analysts price targets for RMTI
or view top-rated stocks among Wall Street analysts.

How have RMTI shares performed in 2022?

Rockwell Medical's stock was trading at $4.51 on January 1st, 2022. Since then, RMTI shares have decreased by 76.7% and is now trading at $1.05.
View the best growth stocks for 2022 here
.

Are investors shorting Rockwell Medical?

Rockwell Medical saw a increase in short interest in November. As of November 15th, there was short interest totaling 127,800 shares, an increase of 29.6% from the October 31st total of 98,600 shares. Based on an average daily volume of 68,700 shares, the short-interest ratio is currently 1.9 days. Approximately 1.2% of the company's stock are short sold.
View Rockwell Medical's Short Interest
.

When is Rockwell Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our RMTI earnings forecast
.

How were Rockwell Medical's earnings last quarter?

Rockwell Medical, Inc. (NASDAQ:RMTI) issued its quarterly earnings data on Monday, November, 15th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.77) by $0.11. The company had revenue of $15.99 million for the quarter, compared to analyst estimates of $18.06 million. Rockwell Medical had a negative net margin of 36.70% and a negative trailing twelve-month return on equity of 297.10%. During the same period in the previous year, the business earned ($1.10) EPS.

When did Rockwell Medical's stock split?

Shares of Rockwell Medical reverse split before market open on Friday, May 13th 2022. The 1-11 reverse split was announced on Friday, May 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

What is Robert L. Chioini's approval rating as Rockwell Medical's CEO?

6 employees have rated Rockwell Medical Chief Executive Officer Robert L. Chioini on Glassdoor.com. Robert L. Chioini has an approval rating of 22% among the company's employees. This puts Robert L. Chioini in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Rockwell Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rockwell Medical investors own include Immunomedics (IMMU), JinkoSolar (JKS), Seagen (SGEN), Geron (GERN), OPKO Health (OPK), Amarin (AMRN), Gilead Sciences (GILD), ImmunoGen (IMGN), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

What is Rockwell Medical's stock symbol?

Rockwell Medical trades on the NASDAQ under the ticker symbol "RMTI."

Who are Rockwell Medical's major shareholders?

Rockwell Medical's stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (10.19%), Richmond Brothers Inc. (6.64%), Perkins Capital Management Inc. (3.34%), Vanguard Group Inc. (2.36%), Verdence Capital Advisors LLC (0.68%) and Jane Street Group LLC (0.22%). Insiders that own company stock include David S Richmond and Russell H Ellison.
View institutional ownership trends
.

How do I buy shares of Rockwell Medical?

Shares of RMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rockwell Medical's stock price today?

One share of RMTI stock can currently be purchased for approximately $1.05.

How much money does Rockwell Medical make?

Rockwell Medical (NASDAQ:RMTI) has a market capitalization of $9.88 million and generates $61.93 million in revenue each year.

How many employees does Rockwell Medical have?

The company employs 300 workers across the globe.

How can I contact Rockwell Medical?

Rockwell Medical's mailing address is 411 HACKENSACK AVENUE SUITE 501, HACKENSACK NJ, 07601. The official website for the company is www.rockwellmed.com. The company can be reached via phone at (248) 960-9009, via email at invest@rockwellmed.com, or via fax at 248-960-9119.

This page (NASDAQ:RMTI) was last updated on 12/2/2022 by MarketBeat.com Staff